State Street’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

State Street’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-412,743	Closed	-$37K	–	4594
2023 Q3	$37K	Hold	412,743	–	–	﹤0.01%	4348
2023 Q2	$38K	Buy	412,743 +388,900	+1,631%	+$62K	﹤0.01%	4487
2023 Q1	$6.2K	Hold	23,843	–	–	﹤0.01%	4763
2022 Q4	$5.01K	Hold	23,843	–	–	﹤0.01%	4833
2022 Q3	$6K	Hold	23,843	–	–	﹤0.01%	4914
2022 Q2	$17K	Hold	23,843	–	–	﹤0.01%	4894
2022 Q1	$19K	Hold	23,843	–	–	﹤0.01%	4889
2021 Q4	$24K	Hold	23,843	–	–	﹤0.01%	4770
2021 Q3	$42K	Hold	23,843	–	–	﹤0.01%	4653
2021 Q2	$44K	Buy	+23,843	New	+$42.1K	﹤0.01%	4439
2019 Q2	–	Sell	-3,250	Closed	-$9K	–	3895
2019 Q1	$9K	Hold	3,250	–	–	﹤0.01%	3731
2018 Q4	$7K	Hold	3,250	–	–	﹤0.01%	3746
2018 Q3	$15K	Sell	3,250 -573	-15%	-$2.17K	﹤0.01%	3750
2018 Q2	$18K	Hold	3,823	–	–	﹤0.01%	3739
2018 Q1	$27K	Hold	3,823	–	–	﹤0.01%	3705
2017 Q4	$27K	Sell	3,823 -35	-0.9%	-$296	﹤0.01%	3678
2017 Q3	$32K	Hold	3,858	–	–	﹤0.01%	3698
2017 Q2	$40K	Hold	3,858	–	–	﹤0.01%	3610
2017 Q1	$45K	Hold	3,858	–	–	﹤0.01%	3583
2016 Q4	$49K	Hold	3,858	–	–	﹤0.01%	3560
2016 Q3	$71K	Hold	3,858	–	–	﹤0.01%	3464
2016 Q2	$41K	Sell	3,858 -100,486	-96%	-$1.97M	﹤0.01%	3602
2016 Q1	$1.97M	Sell	104,344 -554	-0.5%	-$10.7K	﹤0.01%	3013
2015 Q4	$2.79M	Buy	104,898 +816	+0.8%	+$28.3K	﹤0.01%	2858
2015 Q3	$4.75M	Sell	104,082 -102	-0.1%	-$3.85K	﹤0.01%	2544
2015 Q2	$3.35M	Buy	104,184 +1,785	+2%	+$51.9K	﹤0.01%	2847
2015 Q1	$3.26M	Buy	102,399 +7,010	+7%	+$237K	﹤0.01%	2806
2014 Q4	$3.61M	Sell	95,389 -49	-0.1%	-$1.35K	﹤0.01%	2744
2014 Q3	$2.52M	Buy	95,438 +3,235	+4%	+$85.6K	﹤0.01%	2892
2014 Q2	$2.73M	Sell	92,203 -536	-0.6%	-$17.3K	﹤0.01%	2910
2014 Q1	$3.43M	Buy	92,739 +5,305	+6%	+$201K	﹤0.01%	2785
2013 Q4	$3.62M	Buy	87,434 +453	+0.5%	+$17.7K	﹤0.01%	2752
2013 Q3	$4.61M	Buy	86,981 +6,362	+8%	+$371K	﹤0.01%	2573
2013 Q2	$4.31M	Buy	+80,619	New	+$4.03M	﹤0.01%	2550

Other funds holding NAVB

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

State Street's NAVB Position: Q4 2023 in Review

State Street sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 412,743 shares — an estimated $37K sold.

State Street first reported a position in NAVB in Q2 2013 and held it in 34 quarters. The position peaked at $4.75M in Q3 2015. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

State Street reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
State Street sold 412,743 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $37K.
State Street first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 34 quarters.
State Street's Navidea Biopharmaceuticals Inc. position peaked at $4.75M in Q3 2015.
4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on State Street's 13F filing for Q4 2023, filed 14 Feb 2024.